Grants and Contributions:

Back to search

Title:

Dry AMD manufacturing development and optimization

Agreement Number:

1041947

Agreement Value:

$150,000.00

Agreement Date:

Apr 1, 2026 - Jan 31, 2027

Description:

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The Ripple pipeline currently has a number of drug conjugates under development targeting key ocular indications including dry age-related macular degeneration (dry AMD). AMD is the leading cause of vision loss in people over the age of 55, affecting approximately 2.5 million Canadians. It is estimated that up to 90% of AMD cases are dry AMD, and there are no therapeutic treatment options for dry AMD. Scientific and engineering resources will perform work on the manufacturability of Ripple’s complement factor B conjugates (RTC-CFBs) for the treatment of dry AMD.

Organization:

National Research Council Canada

Expected Results:

The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.

Location:

Toronto, Ontario, CA M5G 1L7

Reference Number:

172-2026-2027-Q1-1041947

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

760459073

Recipient Type:

For-profit organization

Recipient's Operating Name:

Ripple Therapeutics

Recipient's Legal Name:

Ripple Therapeutics Corporation

Federal Riding Name:

University--Rosedale

Federal Riding Number:

35110

Program:

Industrial Research Assistance Program

Program Purpose:

The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.

Coverage:

Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity.

NAICS Code:

32541